Introduction
Transmembrane receptor tyrosine kinases normally are activated by ligand binding to their extracellular domain. This results in receptor dimerization, which is thought to be an essential step in activation of receptor tyrosine kinase activity and receptor autophosphorylation (Ullrich and Schlessinger, 1990; Heldin, 1995) . In addition to playing important roles in controlling proliferation and dierentiation of normal cells, growth factor receptors are frequent targets of oncogenic activation. For example, cellular genes encoding the receptors for epidermal growth factor (EGF) and colony stimulating factor 1 (CSF-1) have been transduced by retroviruses, thereby giving rise to the viral oncogenes v-ErbB, and v-fms, respectively (Downward et al., 1984; Sherr et al., 1985) . Genetic rearrangements and point mutations also can generate activated versions of receptor tyrosine kinases. A number of these events are thought to promote receptor dimerization. For example, the c-Met protooncogene product can be activated by a chromosomal translocation that results in fusion of its catalytic domain with a leucine zipper protein dimerization domain (Rodrigues and Park, 1993) . In addition, p185
neu , a receptor tyrosine kinase related to the EGF receptor, can be activated by a Val to Glu substitution at position 664 in the transmembrane (TM) domain (Bargmann et al., 1986) . The resulting mutant, designated p185 neu* , displays increased tyrosine kinase, autophosphorylation and transforming activity. Because p185 neu* has an increased propensity to form dimers, the activating mutation is thought to induce receptor activation by facilitating receptor dimerization (Weiner et al., 1989; Cao et al., 1992b) . Similarly, a Gly to Arg point mutation at position 380 in the TM domain of the ®broblast growth factor receptor 3 (FGFR3), the genetic alteration associated with achondroplasia (Rousseau et al., 1994; Shiang et al., 1994) , results in receptor activation and is thought to be functionally analogous to the p185 neu* mutation (Webster and Donoghue, 1996) .
One of the best characterized receptor tyrosine kinases is the platelet-derived growth factor (PDGF) b receptor (PDGFbR) which undergoes ligand-induced dimerization and tyrosine autophosphorylation at multiple sites (Heldin, 1992) . Despite extensive analysis of the PDGF receptor, activated alleles of the PDGFbR gene have proven to be elusive. The PDGFbR gene has not been transduced by known oncogenic retroviruses, and no PDGFbR mutants have been constructed that are capable of tumorigenic transformation in cultured cells. However, growth transformation clearly can result from constitutive activation of the PDGFbR caused by expression of the v-sis oncogene, which encodes an oncogenic form of PDGF (Doolittle et al., 1983; Water®eld et al., 1983) , or by expression of the E5 transforming protein of bovine papillomavirus (BPV), which forms a complex with this receptor in transformed cells and activates it (Petti et al., 1991; Petti and DiMaio, 1992; Nilson and DiMaio, 1993) . Recently, a chromosomal translocation has been identi®ed in human myelomonocytic leukemia cells that generates a protein comprised of the N-terminal domain of an ets-related transcription factor fused to the TM and the cytoplasmic domains of the PDGFbR (Golub et al., 1994) . Heterologous expression of this fusion protein in a hematopoietic cell line results in its constitutive tyrosine phosphorylation and in ligand-independent proliferation. Both of these activities require the ETS helix ± loop ± helix self-association domain as well as the PDGFbR tyrosine kinase domain of the fusion protein (Carroll et al., 1996) . However, this fusion protein is unable to transform NIH3T3 ®broblasts, and its role in the pathogenesis of human leukemia has not been established.
The absence of known activating PDGFbR point mutations raised the possibility that some special feature(s) of the PDGFbR might preclude its activation by mechanisms commonly observed with other receptor tyrosine kinases. Therefore, we decided to test whether the activating mutation of p185 neu* could drive constitutive activation of the PDGFbR. Here, we report that replacing the TM domain of the PDGFbR with that of p185 neu* stimulates PDGFbR tyrosine autophosphorylation and induces striking biological eects in cells such as morphologic cell transformation, focus formation, growth factor-independent cell proliferation and tumorigenicity. Figure 1a shows schematically the structure of the chimeric receptors in comparison with wild type PDGFbR, p185 neu and p185 neu*
Results

Structure of the chimeric receptors
. The TM domain of the wild type PDGFbR was replaced with that of p185 neu* to generate PR/neu*. We also constructed PR/ neu, a chimeric receptor containing the TM domain of wild type p185 neu . Sequence analysis of the TM region of these chimeras (Figure 1b) revealed that PR/neu* diers from PR/neu only by the expected valine to glutamic acid substitution.
Transforming activity of the PR/neu* chimera in C127 cells
The biological eects of the chimeric PDGFbR were ®rst assessed in C127 cells, a morphologically normal, non-tumorigenic, murine ®broblast cell line. Constitutive activation of the endogenous PDGFbR in these cells by expression of v-sis or the BPV E5 oncogene results in cellular transformation (Riese and DiMaio, 1995; Petti et al., 1991) . C127 cells were infected at the same multiplicity with recombinant retroviruses expressing wild type PDGFbR, PR/neu and PR/neu*, and cell monolayers were maintained at con¯uence in the absence of biochemical selection. Figure 2 shows that, like the control vector, neither the PDGFbR nor PR/ neu induced focus formation in C127 cells (Figure 2a, b, and c, respectively) . In contrast, PR/neu* readily induced the formation of dense foci of piled-up cells (Figure 2d ). In addition, C127 cell lines stably expressing the various receptor constructs were established by retrovirus infection followed by selection for a cotransduced drug resistance marker. Cells expressing exogenous wild type PDGFbR (Figure 3b ) or PR/neu (Figure 3c ) resembled cells containing the retroviral vector alone (Figure 3a ) and remained¯at and nonrefractile. In contrast, cells expressing PR/neu* exhibited a transformed morphology, appearing more dense, refractile, and spindle-shaped (Figure 3d ). Thus, a PDGFbR chimera containing the TM domain of p185 neu* has transforming activity in C127 cells, whereas the TM domain from wild type p185 neu did not confer this activity on the PDGFbR.
Tumorigenicity of cells expressing the PR/neu* chimera
We also assessed the ability of the stable C127 cell lines shown in Figure 3 to form tumors when injected in Therefore, it appears that PR/neu* in C127 cells undergoes ligandindependent tyrosine autophosphorylation. Similar results were obtained in three sets of independentlyderived C127 cell lines. Thus, assessment of receptor tyrosine phosphorylation con®rms that the p185 neu* TM substitution activates the PDGFbR.
Biological activity of the PR/neu* chimera in Ba/F3 cells Since the exogenous PDGFbR in C127 cells could not be distinguished from the endogenous wild type receptor, we assessed the activity of the chimeric receptors in Ba/F3 cells, which do not express endogenous PDGFbR. Ba/F3 cells are mouse hematopoietic cells which depend on interleukin 3 (IL-3) for continued viability and sustained proliferation (Palacios and Steinmetz, 1985) . This requirement can be alleviated by expression of the wild type PDGFbR in the presence of v-sis or the BPV E5 protein (Drummond-Barbosa et al., 1995) . Ba/F3 cell lines stably expressing the various receptors were generated and examined for proliferation during a 7 day incubation in medium lacking IL-3 ( Figure 5 ). Ba/F3 cells expressing the vector alone, the wild type PDGFbR, or PR/neu proliferated only to a very limited extent. In contrast, approximately tenfold more cells were present in cultures of cells expressing PR/neu*, indicating that the TM domain of p185 neu* was able to activate the PDGFbR in Ba/F3 cells, as well as C127 cells. This result was obtained in nine independently-derived sets of cell lines. In addition, cells expressing PR/neu* could be serially passaged in the absence of IL-3, thereby establishing stable IL-3 independent cell lines. To con®rm that the various receptor constructs were functional, they were also introduced into cells constitutively expressing v-sis. Expression of v-sis in Ba/F3 cells without exogenous receptor did not allow proliferation (data not shown), but coexpression of the wild type receptor or PR/neu with v-sis resulted in a signi®cant increase in cell number ( Figure 5 ) as well as increased receptor tyrosine phosphorylation (data not shown). Therefore, both the wild type receptor and PR/neu responded normally to PDGF, indicating that their inability to support growth in the absence of ligand was not due to an intrinsic defect in their biochemical activity as signaling tyrosine kinases.
Microscopic examination of cell cultures incubated in the absence of IL-3 demonstrated that viable cells were not present in cultures expressing the wild type PDGFbR or the vector alone, whereas there were numerous viable cells in the culture expressing PR/ neu*. A few viable cells were also present in some cultures expressing PR/neu alone, suggesting that this chimera was not biologically inert in the absence of vsis. Such cultures became dense upon an additional week of incubation in the absence of IL-3, whereas the other PR/neu cultures did not proliferate even after an extended incubation period (data not shown). The ability of such cultures to proliferate did not correlate with the level of PR/neu expressed, since most cultures expressed approximately equivalent amounts of transduced receptor (data not shown). Therefore, although PR/neu did not display the same biological activity as PR/neu* in Ba/F3 cells, it was able to confer limited IL-3 independence. Cells infected with control retrovirus vector alone did not express detectable PDGFbR (data not shown), and equal amounts of total exogenous receptor were expressed in the dierent cell lines (Figure 6 , left panel). Strikingly, tyrosine phosphorylation of PR/ neu* was dramatically increased compared to that of the wild type receptor or the PR/neu chimera ( Figure  6 , right panel). Thus, PR/neu* was constitutively activated and able to induce a proliferative signal in Ba/F3 cells, as it was in C127 cells.
Phosphotyrosine immunoblotting of PDGF receptor immunoprecipitates also revealed a doublet of tyrosine phosphorylated proteins of approximately 60 kilodaltons (kDa) coimmunoprecipitating with the PR/ neu* chimera and not with the PR/neu chimera ( Figure  7a ). These 60 kDa proteins are unlikely to be forms of the receptor itself since they could not be detected in Figure 5 IL-3 independent proliferation of Ba/F3 cells expressing the various PDGF receptor constructs. Ba/F3 cells (7) or Ba/F3 cells expressing v-sis (+) were infected with a retrovirus vector without an insert or with vectors expressing the indicated PDGFbR construct. After selection for G418 resistance in the presence of IL-3, 10 5 cells/ml of each cell line were incubated in the absence of IL-3 for 7 days and counted. Cells expressing v-sis without exogenous receptor failed to proliferate (data not shown). mPRb indicates the wild type murine PDGFbR receptor immunoprecipitates from denatured cell extracts nor did they comigrate with the major degradation products of the receptor (data not shown). Similar-sized phosphotyrosine proteins were not detected in immunoprecipitates of the wild type receptor activated by the BPV E5 protein or by the vsis-encoded protein (Figure 7b ). This suggests that activation of the PDGFbR by the Neu* TM substitution, compared to other means of activation, increases the receptor's anity for the 60 kDa proteins and/or increases tyrosine phosphorylation or expression of these proteins. Speci®c antibodies against known 60 kDa tyrosine phosphorylated proteins such as pp60 src and related proteins, the recently identi®ed ras GAP-associated protein p62
dok (Carpino et al., 1997; Yamanashi and Baltimore, 1997) , the protein tyrosine phosphatase Syp/SHPTP2, and paxillin did not appear to react with these PR/neu* associated proteins (data not shown), suggesting that the components of the activated PR/neu* complex may include some uncharacterized tyrosine-phosphorylated proteins.
The intrinsic tyrosine kinase activity of PR/neu* also was assessed by an in vitro kinase assay in which PDGF receptor immunoprecipitates prepared from Ba/ F3 cells were incubated in the presence or absence of ATP and then subjected to anti-phosphotyrosine immunoblotting (Figure 8) . The left panel of Figure 8 shows receptor tyrosine phosphorylation in the absence of ATP and illustrates the increased tyrosine phosphorylation of the constitutively activated receptors. The right panel shows tyrosine phosphorylation following incubation of the receptor immunoprecipitates with ATP. To calculate the amount of phosphotyrosine that was added during the in vitro reaction, the bands were quanti®ed by PhosphorImager and the level of receptor tyrosine phosphorylation in the absence of ATP was subtracted from the level of tyrosine phosphorylation obtained after incubation with ATP. This analysis showed that the v-sisactivated wild type PDGF receptor and PR/neu* both catalyzed approximately 2 ± 3-fold more tyrosine autophosphorylation in vitro than did the wild type receptor without ligand treatment. Similar results were obtained in several independent experiments. These results suggest that the PR/neu* substitution has a similar eect as v-sis in increasing the intrinsic tyrosine kinase activity of the PDGFbR. Tyrosine phosphorylation of the precursor form of PR/neu* and of the v-sisactivated receptor, but not the wild type receptor without ligand was induced in the presence of ATP, further indicating an increase in the chimeric receptor's kinase activity. Interestingly, tyrosine phosphorylation of the 60 kDa proteins associated with PR/neu* also was induced in vitro in the presence of ATP.
Discussion
To determine whether the PDGFbR could be activated by mutation, we replaced the TM domain of the PDGFbR with the TM domain of oncogenic p185 neu* . This substitution resulted in constitutive PDGFbR activation in two dierent murine cell lines, giving rise to morphologic transformation, focus formation, and tumorigenicity in C127 cells and IL-3 independent proliferation of Ba/F3 cells. In both cell types, PR/ neu* had increased levels of phosphotyrosine, and in Ba/ F3 cells the intrinsic tyrosine kinase activity of PR/neu* was elevated compared to the wild type receptor. Thus, discrete alterations in the TM domain are sucient to activate the PDGFbR. Because the valine to glutamic acid substitution in the TM domain stimulates p185 neu* dimerization, we speculate that this mutant domain in the framework of the PDGFbR enhances constitutive homodimerization of the receptor chimera, thereby stimulating kinase activity and mitogenic signaling. The notion that growth factor receptor activation can be induced by arti®cially promoting speci®c TM interactions is further supported by the ®nding that fusion of the cytoplasmic domain of the CSF-1 receptor to the extracellular and TM domains of glycophorin A, the latter of which is capable of constitutive dimerization, results in receptor activation (Lee and Nienhuis, 1992; Bormann et al., 1989) .
The TM domain of p185 neu* has been previously introduced into growth factor receptors with various outcomes. A previous attempt to activate the PDGFbR with the TM domain of p185 neu* was inconclusive since the mutant receptor harbored an additional mutation in the kinase domain (Escobedo et al., 1988) . A chimera of the Drosophila EGF receptor homologue (DER) containing the TM and extracellular juxtamembrane domains from either p185 neu* or p185 neu displayed increased, constitutive tyrosine phosphorylation in insect cells but not monkey cells (Wides et al., 1990) . However, the biological activities of these DER/Neu chimeras were not assessed. Cheatham et al. (1993) replaced the TM domain of the insulin receptor with that of p185 neu* and showed that the resulting chimeric receptor displayed high levels of tyrosine autophosphorylation and kinase activity in the absence of insulin, and cells expressing this mutant displayed a resistance to the metabolic eects of insulin. However, the absolute level of DNA synthesis in the absence of insulin was not increased in cells expressing the chimeric insulin receptor compared to cells expressing the wild type receptor. Furthermore, the insulin receptor exists in cells as a preformed tetramer, so the biochemical mechanism of insulin receptor activation by the TM domain of p185 neu* is likely to dier in some aspects from the mechanism of activation of p185 neu* and PDGFbR, which are monomeric in the inactive state.
In p185 neu* itself, the valine to glutamic acid activating mutation is thought to facilitate interactions between TM alpha-helices, thus stabilizing receptor dimers suciently to induce activation in the absence of ligand (Lemmon and Engleman, 1994) . The glutamic acid sidechains may form novel hydrogen bonds between alpha-helices (Sternberg and Gullick, 1989) or the mutation may induce or stabilize an alpha helical conformation that enhances interreceptor packing (Brandt-Rauf et al., 1990) . Mutational analysis of p185 neu* indicates that the amino acids directly¯anking Glu664 are also required for transforming activity (Cao et al., 1992a) . However, these studies did not exclude the possibility that other regions of p185 neu* , in addition to the TM domain, were required for the eects induced by the activating mutation. The results presented here demonstrate that the TM domain is the only sequence from p185 neu* that is required for activation in the context of the PDGFbR. By characterizing additional PDGFbR chimeras containing varying extents of the p185 neu* TM domain, we may be able to determine the minimal sequences derived from this TM domain that are sucient to drive receptor activation.
Only the chimeric receptor containing the TM domain with the activating mutation exhibited transforming activity in C127 cells and displayed elevated tyrosine phosphorylation. However, the chimera containing wild type TM domain from p185 neu was able to induce some IL-3 independent survival and proliferation of Ba/F3 cells. It is possible that PR/neu displayed limited activity measurable only in Ba/F3 cells, which appear to be a more sensitive indicator for PDGF Figure 8 In vitro tyrosine kinase activity of PR/neu*. PDGF receptor immunoprecipitates from extracts of Ba/F3 cells expressing either the wild type receptor (mPRb) or PR/neu* alone, or the wild type receptor with v-sis (PR+sis) were incubated in the absence (7) or presence (+) of ATP and then subjected to anti-phosphotyrosine immunoblotting. Tyrosine phosphorylated PDGF receptor and the 60 kDa proteins associated with PR/neu* are indicated by arrows at the top and bottom, respectively, of the blot on the right receptor activation than C127 cells (Irusta and DiMaio, unpublished) . This eect appears to be speci®c for the TM domain of Neu since a chimeric receptor containing the TM domain of the EGF receptor in the context of the PDGF receptor does not display signi®cant activity (Petti et al., 1997) . Activation of p185 neu containing the wild type TM domain evidently can occur in other systems since overexpression of wild type p185
neu results in transformation of NIH3T3 cells (Hudziak et al., 1987; DiFiore et al., 1990) and is associated with breast and ovarian carcinoma (Hynes and Stern, 1994) . In addition, the wild type TM domain from p185 neu previously has been shown to induce partial activation when inserted into other growth factor receptors. For example, an insulin receptor chimera containing the TM domain of p185 neu displayed enhanced activity in in vitro kinase assays but not in intact cells (Yamada et al., 1992) . Our results indicate that the TM domain of the wild type PDGFbR has little intrinsic ability to support receptor activation in the absence of ligand. In contrast, the wild type TM domain from p185 neu induces weak activity that can be measured in a biological assay in Ba/F3 cells but not in C127 cells, and this activity can be augmented to full-scale transforming activity by the Val to Glu substitution. Thus, the p185 neu TM domain inherently may facilitate receptor dimerization to a greater degree than most other receptor TM domains but to a lesser degree than the TM domain from the activated p185 neu* . A constitutively active receptor mutant such as PR/ neu* may be a useful reagent for future investigations of PDGFbR activation. Normally, PDGF treatment results in transient tyrosine phosphorylation of the mature, cell surface form of the PDGFbR. Tyrosine phosphorylated PR/neu* appears to correspond primarily to this mature form (although some tyrosine phosphorylation of an apparent intracellular precursor form can occur in vitro with the addition of ATP (Figure 8) ). In this regard, PR/neu* diers from PDGFbR constitutively activated by v-sis or BPV E5. In v-sis-transformed cells, the receptor is unstable and is often present as incompletely processed intracellular forms (Keating and Williams, 1988) , and a precursor receptor form with immature carbohydrates is a prominent form of activated receptor in cells transformed by BPV E5 (Petti et al., 1991; Nilson and DiMaio, 1993) . Therefore, cells expressing the activated chimera may be an abundant source of receptor that closely resembles receptor activated by ligand. A further advantage to using the PR/neu* chimera is that cells expressing it presumably contain only activated PDGFbR. In contrast, the use of PDGF to activate the b receptor invariably also activates the related PDGF a receptor which has distinct biological properties. In addition, targeted expression of this activated chimera in speci®c cell types in transgenic animals may allow analysis of PDGFbR function without complications arising from more promiscuous activation of endogenous receptors that would occur in response to ligand expression. Finally, such a persistently activated receptor may be useful for identifying inhibitors of PDGFbR signaling.
PR/neu* also may be useful for characterizing the components of the activated PDGFbR complex and the mechanism of PDGFbR signaling. For example, comparison of ligand-activated receptor to receptor activated in a ligand-independent manner by BPV E5 or the p185 neu* TM domain may allow the identi®cation of common essential features of PDGFbR signaling. Alternatively, if PDGFbR activated by dierent means utilizes dierent signaling pathways to promote cell proliferation, PR/neu* may allow identi®cation of new intracellular signaling pathways. For example, the 60 kDa tyrosine phosphorylated proteins shown here to speci®cally associate with the PR/neu* may represent novel PDGFbR substrates involved in distinct signaling pathways.
Materials and methods
Construction of chimeric receptor mutants
Chimeric receptors, PR/neu* and PR/neu, were constructed by replacing the TM domain of the murine PDGFbR with that of p185 neu* and its wild type counterpart, respectively. First, standard recombinant PCR mutagenesis was used to delete a DNA fragment containing the TM domain and 13 ± 14¯anking base pairs from a wild type murine PDGFbR cDNA construct, pSVR1 (gift from LT Williams, UCSF), creating a unique NdeI site. Synthetic double-stranded oligonucleotides were inserted into this NdeI site, generating clone pPRNTM encoding PR/neu*, in which the PDGFbR TM domain was precisely replaced with that of p185 neu* (Figure 1b) . PR/neu, a chimeric receptor containing the TM domain of the wild type p185 neu , was constructed by recombinant PCR mutagenesis using pPRNTM as a template and an internal primer containing a mismatch at position 2012 of the rat cDNA sequence (Bargmann et al., 1986) . The biological properties of PR/neu in the presence and absence of the BPV E5 protein are described in Petti et al. (1997) where this chimera is referred to as PR-neuTM. The desired DNA sequence in the segment replaced by the oligonucleotide insertion or PCR ampli®cation was con®rmed. Standard subcloning procedures were used to subclone the wild type mouse PDGFbR from pSVR1 into the retroviral vector pLXSN to generate pMPRRV-3. The wild type PDGFbR gene in pPMPRRV-3 was replaced with PR/neu* or PR/ neu to generate pNTMRV-14 and pNNTMRV-9, respectively. Stable cell lines producing high titer ecotropic retrovirus stocks were obtained after selection for G418 resistance as described (Leptak et al., 1991) .
Stable cell lines
C127 cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and antibiotics (DME-10). Ba/F3 cells (Palacios and Steinmetz, 1985) were obtained from Alan D'Andrea (Dana Farber Cancer Institute) and maintained as previously described (Drummond-Barbosa et al., 1995) in RPMI supplemented with 10% heat inactivated fetal bovine serum, WEHI conditioned medium as a source of IL-3, 0.05 mM b-mercaptoethanol, and antibiotics (RPMI/ IL-3).
C127 cell lines expressing exogenous wild type mouse PDGFbR, PR/neu*, or PR/neu were established as described (Leptak et al., 1991) by infection at approximately equal multiplicities with the recombinant retroviruses MPRRV-3, NTMRV-14, and NNTMRV-9, respectively. A control cell line was established by infection with the LXSN retrovirus vector without an insert. Stable cell lines were obtained after 12 days of drug selection by pooling approximately 200 ± 500 G418-resistant colonies.
Stable Ba/F3 cell lines expressing the various receptor constructs in the absence or presence of v-sis were established by infecting BaD5RVY or BaD5v-sis cells (the latter of which constitutively express v-sis; gifts from D DrummondBarbosa), respectively, with recombinant retroviruses as previously described (Drummond-Barbosa et al., 1995) with minor modi®cations. Brie¯y, approximately 2610 6 CFU (colony forming units) of retrovirus was added to 10 6 to 5610 6 cells in 10 ml of RPMI/IL-3 containing 4 mg/ml of Polybrene. After 2 days, 1 ml of infected cells was transferred into 10 ml of RPMI/IL-3 containing 1 mg/ml G418 and 1000 units/ml of hygromycin B (Calbiochem). Cells were passaged during drug selection when they reached a density of approximately 10 6 cells/ml and after 3 ± 5 passages stable cell lines were established.
Focus forming assay
C127 cells at 40 ± 50% con¯uence in 6 cm dishes were infected with approximately 5610 4 CFU of recombinant retrovirus. Two days after infection the cells were split 1 : 3 and maintained at con¯uence in DME-10. Foci were visible 2 weeks after infection and approximately 1 week later were ®xed in methanol and stained with 2% (vol/vol) Giesma.
Tumorigenicity assay
Stable C127 cells expressing the receptor constructs were trypsinized, pelleted, and resuspended in PBS. Approximately 2610 6 cells per site were injected subcutaneously into 6 ± 8 week-old female Balb/c nude mice (two sites/ mouse) (Life Sciences, St Petersburg, FL). Eight weeks after injection, masses larger than 8 mm in diameter were scored as positive. Sites with no visible tumor formation were scored as negative.
Immunoprecipitation and immunoblotting
Extracts of C127 cells and Ba/F3 cells were prepared in cold EBC buer as described (Petti et al., 1991; Petti and DiMaio, 1994; Drummond-Barbosa et al., 1995) . The PDGFbR was immunoprecipitated as previously described (Petti et al., 1991; Petti and DiMaio, 1994) by adding 10 ml of a-PR-C3a antibody to 70 or 700 mg of protein extract of C127 or Ba/F3 cells, respectively. Washed immunoprecipitates were boiled in 26Laemmli sample buer, electrophoresed on an SDS-7.5% polyacrylamide-0.17% bisacrylaminde gel and transferred to nitrocellulose at 50 V overnight or 100 V for 2 h. Phosphotyrosine and PDGFbR immunoblotting was performed as described DiMaio, 1992, 1994) by using a 1 : 500 dilution of anti-phosphotyrosine monoclonal antibody 4G10 (Upstate Biotechnology, Inc.) and a 1 : 250 dilution of a-PR-C3a, respectively. Proteins were detected with 125 IProtein A (ICN) (Figure 4) or enhanced chemiluminescence using a Protein A-horseradish peroxidase (HRP) conjugate (Amersham).
In vitro kinase assay
Ba/F3 cells expressing the wild type receptor, the wild type PDGFb receptor and v-sis, or the PR/neu* chimera were serum-starved overnight in RPMI/IL3 supplemented with 1% fetal bovine serum. Cells then were washed twice with PBS and extracts were prepared as described above except that EB buer (10 mM Tris-Cl, pH 7.4; 50 mM NaCl; 5 mM EDTA; 1% Triton X-100; 50 mM NaF; 2 mM Na 3 VO 4 ; 1 mM PMSF; 5 mg/ml aprotinin; 5 mg/ml leupeptin) was used to lyse the cells. PDGF receptor was immunoprecipitated from 1 mg of extract and a kinase assay was performed by incubating one tenth of the immunoprecipitate in the absence or presence of 50 mM rATP as described (Drummond-Barbosa et al., 1995) except that no exogenous substrate was added to the reaction. Kinase reaction products were electrophoresed and subjected to antiphosphotyrosine immunoblotting as described above. A portion of each PDGF receptor immunoprecipitate used for the kinase reaction was subjected to PDGF receptor immunoblotting to determine the amount of receptor in the reaction mix. Immunoblots were subjected to PhosphorImager analysis, and the amount of tyrosine phosphorylation catalyzed in vitro was calculated as described in the text and normalized for receptor amount in each immunoprecipitate.
Assay for IL-3 independent growth
The ability of Ba/F3 cells to proliferate in the absence of IL-3 was assessed as described previously (DrummondBarbosa et al., 1995) with some modi®cations. Cells were grown to a density of approximately 10 6 cells/ml, pelleted, washed with PBS, and resuspended in an equal volume of RPMI medium formulated as above except WEHI conditioned media was omitted (RPMI/IL-3-). Approximately 10 6 cells were seeded into 10 ml of RPMI/IL-3-, incubated at 378C for 7 days, and then counted in a hemocytometer.
